C16 Biosciences Brews a Palm Oil Alternative in a Manhattan Fermenter

The New York biotech, backed by Gates and Breakthrough Energy, has scaled to 50,000-liter batches and is now chasing FDA approval for food.

About C16 Biosciences

Published

The Analyst's Last Word

Conviction:...

Agentic / AI relevance

The most common vegetable oil in the world is also one of the most destructive. Palm oil, a $61 billion global industry, is the reason a football field of rainforest is cleared every six seconds [C16 Biosciences]. It is also the irreplaceable workhorse in thousands of consumer products, from lipstick and shampoo to ice cream and instant noodles.

C16 Biosciences, a New York biotech, has spent the last six years trying to brew a way out of that dilemma. In a 20,000-square-foot facility in Midtown Manhattan, they feed sugar to a proprietary strain of yeast. The microbe excretes an oil that is chemically and functionally identical to the palm-derived fats used by major brands. They call it Palmless™.

The Manhattan Fermenter

C16’s bet is a classic climate tech wedge: find a massive incumbent industry with an environmental liability, then build a drop-in replacement that solves the liability without asking the customer to change their product. Palm oil is responsible for roughly 5% of global deforestation [C16 Biosciences].

The company’s platform, precision fermentation, is the same basic technology used to make insulin, rennet for cheese, and heme for Impossible Burgers. C16’s founders, CEO Shara Ticku, COO David Heller, and CSO Harry McNamara, have focused on optimizing the yeast strain and the fermentation process. Their first commercial product, Torula Oil, launched in beauty formulations in 2023 [SPEEDA Edge, Jan 2024]. They have run 50,000-liter industrial fermentation batches [SPEEDA Edge, Jan 2024].

The Beauty Wedge and the Food Frontier

C16’s initial market entry through beauty and personal care is a tactical move. The company says its Palmless™ oils are now trusted by leading brands in beauty, home care, and food [gopalmless.com, 2026].

The real prize, however, is the food aisle. Nearly three-quarters of all palm oil ends up in food products. The company is actively pursuing Generally Recognized As Safe (GRAS) status from the U.S. Food and Drug Administration [zoonop.com, 2026].

The Backing of Patient Capital

C16 has raised over $30 million to date [PitchBook, 2024]. Their Series A in 2020 was led by Breakthrough Energy Ventures. In early 2024, they secured a $3.5 million grant from the Bill & Melinda Gates Foundation, followed by a $1 million venture investment from Elemental Excelerator [Crunchbase, 2024] [Green Queen, Jan 2024].

Round Date Amount Lead Investor(s)
Series A March 2020 $20,000,000 Breakthrough Energy Ventures
Grant January 2024 $3,500,000 Bill & Melinda Gates Foundation
Venture October 2023 $1,000,000 Elemental Excelerator

Where the Economics Get Slippery

The core challenge is cost. Palm oil is notoriously cheap, often trading below $1,000 per metric ton. To win, C16 must drive its production costs down through relentless strain engineering and process optimization at scale.

The company’s answer rests on three pillars:

  • Performance parity. Their oils must function identically to palm-derived ingredients in final products.
  • Supply chain premium. Brands may pay a modest premium for a guaranteed, deforestation-free supply.
  • Regulatory moat. Successfully navigating FDA GRAS and other global food safety approvals creates a significant barrier for later entrants.

The Next Twelve Months

For C16, the immediate horizon is defined by regulatory milestones and commercial partnerships. Securing FDA GRAS status for one or more of its Palmless™ oils would be a watershed, unlocking the massive food and beverage market. Concurrently, announcing partnerships with major CPG brands would provide tangible validation of both performance and demand at scale.

Sources

  1. [C16 Biosciences] Company website and press materials | https://c16bio.com/
  2. [SPEEDA Edge, Jan 2024] Company profile and product details | https://edge.speeda.com/
  3. [PitchBook, 2024] Funding and company overview | https://pitchbook.com/profiles/company/232078-96
  4. [Crunchbase, 2024] Funding round details | https://www.crunchbase.com/organization/c16-biosciences
  5. [Green Queen, Jan 2024] Coverage of Elemental Excelerator investment | https://www.greenqueen.com.hk/
  6. [gopalmless.com, 2026] Palmless™ brand and customer claims | https://gopalmless.com
  7. [zoonop.com, 2026] Coverage of FDA GRAS pursuit | https://zoonop.com

Read on Startuply.vc